Detalhe da pesquisa
1.
Structural determinants of dual incretin receptor agonism by tirzepatide.
Proc Natl Acad Sci U S A
; 119(13): e2116506119, 2022 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35333651
2.
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
Diabetes Obes Metab
; 25(4): 1080-1090, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36541037
3.
Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein.
J Pharmacol Exp Ther
; 382(3): 346-355, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35840338
4.
Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union.
Regul Toxicol Pharmacol
; 88: 56-65, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526658
5.
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog.
J Pharmacol Exp Ther
; 357(3): 459-65, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27026683
6.
The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
Endocr Rev
; 45(3): 379-413, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38224978
7.
Comprehensive insulin receptor phosphorylation dynamics profiled by mass spectrometry.
FEBS J
; 289(9): 2657-2671, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34826178
8.
Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.
J Med Chem
; 65(20): 13892-13909, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36197449
9.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.
Cell Metab
; 34(9): 1234-1247.e9, 2022 09 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35985340
10.
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.
J Clin Invest
; 131(12)2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34003802
11.
FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho.
J Cell Physiol
; 215(1): 1-7, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18064602
12.
FGF-21 as a novel metabolic regulator.
J Clin Invest
; 115(6): 1627-35, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15902306
13.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Mol Metab
; 18: 3-14, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30473097
14.
Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
J Clin Invest
; 113(11): 1571-81, 2004 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15173883
15.
Internalization and localization of basal insulin peglispro in cells.
Mol Cell Endocrinol
; 454: 23-38, 2017 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28576743
16.
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual ß-cells persist.
Elife
; 52016 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092792
17.
Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling.
J Cell Physiol
; 210(1): 1-6, 2007 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17063460
18.
Glucagon as a target for the treatment of Type 2 diabetes.
Expert Opin Ther Targets
; 9(3): 593-600, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15948676